Cantor Fitzgerald reiterated their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) in a research note published on Sunday morning. The brokerage currently has a $200.00 price target on the specialty pharmaceutical company’s stock.

JAZZ has been the topic of several other reports. Cowen set a $190.00 price target on shares of Jazz Pharmaceuticals and gave the company a buy rating in a research note on Monday, August 21st. HC Wainwright started coverage on shares of Jazz Pharmaceuticals in a research note on Friday, August 25th. They issued a neutral rating and a $144.00 price target on the stock. Wells Fargo & Company restated a buy rating on shares of Jazz Pharmaceuticals in a research note on Tuesday, August 29th. Stifel Nicolaus restated a buy rating and issued a $190.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday, August 30th. Finally, Royal Bank of Canada restated a buy rating and issued a $210.00 price target on shares of Jazz Pharmaceuticals in a research note on Friday, September 15th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and nineteen have assigned a buy rating to the company. The company presently has an average rating of Buy and a consensus price target of $181.28.

Jazz Pharmaceuticals (NASDAQ JAZZ) opened at $140.63 on Friday. The firm has a market cap of $8,393.07, a PE ratio of 17.57, a PEG ratio of 0.90 and a beta of 0.98. Jazz Pharmaceuticals has a 1 year low of $101.44 and a 1 year high of $163.75. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.10 and a quick ratio of 2.94.

In other news, Director Patrick G. Enright sold 9,000 shares of the firm’s stock in a transaction that occurred on Monday, December 11th. The shares were sold at an average price of $139.73, for a total value of $1,257,570.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Michael Patrick Miller sold 200 shares of the firm’s stock in a transaction that occurred on Monday, December 11th. The shares were sold at an average price of $139.15, for a total transaction of $27,830.00. The disclosure for this sale can be found here. Insiders have sold 18,552 shares of company stock worth $2,549,643 over the last quarter. Corporate insiders own 4.30% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of the company. World Asset Management Inc boosted its stake in shares of Jazz Pharmaceuticals by 1.9% in the 2nd quarter. World Asset Management Inc now owns 1,441 shares of the specialty pharmaceutical company’s stock valued at $224,000 after purchasing an additional 27 shares in the last quarter. Profund Advisors LLC raised its holdings in Jazz Pharmaceuticals by 1.3% in the 2nd quarter. Profund Advisors LLC now owns 2,915 shares of the specialty pharmaceutical company’s stock valued at $453,000 after buying an additional 38 shares during the last quarter. Toronto Dominion Bank raised its holdings in Jazz Pharmaceuticals by 12.4% in the 2nd quarter. Toronto Dominion Bank now owns 736 shares of the specialty pharmaceutical company’s stock valued at $114,000 after buying an additional 81 shares during the last quarter. Advisors Asset Management Inc. raised its holdings in Jazz Pharmaceuticals by 0.5% in the 2nd quarter. Advisors Asset Management Inc. now owns 17,882 shares of the specialty pharmaceutical company’s stock valued at $2,781,000 after buying an additional 86 shares during the last quarter. Finally, Victory Capital Management Inc. raised its holdings in Jazz Pharmaceuticals by 4.0% in the 2nd quarter. Victory Capital Management Inc. now owns 3,410 shares of the specialty pharmaceutical company’s stock valued at $530,000 after buying an additional 132 shares during the last quarter. Institutional investors own 91.30% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Cantor Fitzgerald Reiterates “Buy” Rating for Jazz Pharmaceuticals (JAZZ)” was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.watchlistnews.com/cantor-fitzgerald-reiterates-buy-rating-for-jazz-pharmaceuticals-jazz/1762527.html.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.